Dr. Yuri van der Heijden receives new R01 grant to study drug-resistant tuberculosis!

Dr. van der Heijden has just received a 5-year R01 grant from the NIH entitled, “Poor Treatment Response and Outcomes in Bedaquiline-Based Treatment Regimens for Drug-Resistant Tuberculosis in South Africa” (R01AI158605). This includes partners at the Aurum Institute, University of Cape Town, and Stellenbosch University. In the proposed studies, the group aims to determine the clinical, pharmacokinetic, and mycobacterial genotypic and phenotypic predictors of programmatic poor treatment response and outcomes of drug-resistant tuberculosis in South Africa, which will allow targeted interventions among high-risk individuals